Brophy, D F <br/><br/>
Cost-effectiveness of sevelamer versus calcium carbonate plus atorvastatin to reduce LDL in patients with chronic renal insufficiency with dyslipidemia and hyperphosphatemia.  [electronic resource] 

 -  Pharmacotherapy  Aug 2000 
 - 950-7 p.  digital 
<br/><br/> Publication Type: Comparative Study; Journal Article 
<br/><br/><label>ISSN: </label>0277-0008 
<br/><br/><label>Standard No.: </label>10.1592/phco.20.11.950.35261  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Atorvastatin<br/>Calcium Carbonate--economics<br/>Cost-Benefit Analysis<br/>Decision Support Techniques<br/>Epoxy Compounds--economics<br/>Health Care Costs<br/>Heptanoic Acids--economics<br/>Humans<br/>Hydroxymethylglutaryl-CoA Reductase Inhibitors--economics<br/>Hyperlipidemias--blood<br/>Hypolipidemic Agents--economics<br/>Kidney Failure, Chronic--blood<br/>Lipoproteins, LDL--blood<br/>Phosphates--blood<br/>Polyamines<br/>Polyethylenes--economics<br/>Pyrroles--economics<br/>Sevelamer